top of page

About us

The Neurogenomics And Precision Medicine (NAP-Med) lab, led by Dr. Ziv Gan-Or, is focused on identifying genetic causes and modifiers of neurological disorders, at the population level and at the individual level, towards precision medicine. Using advanced genetic methods such as whole-genome and whole-exome sequencing, targeted next generation sequencing, genome-wide association studies, RNA sequencing and more, we study the genetic and molecular basis of diseases such as Parkinson's disease, REM sleep behavior disorder, restless legs syndrome, dementia with Lewy-bodies, multiple system atrophy, hereditary spastic paraplegia and others. We use these genetic results to identify potential drug targets, identify sub-types of diseases and perform genetic stratification for clinical trials.

20191206_232143.jpg

News

September 22nd 2022 -
Huge congratulations to Dr. Mehrdad Estiar who graduated with a PhD from our lab, and got accepted to the Broad Institute as a postdoctorla fello!

Photo Mehrdad.jpg

Research highlights

  • Our new GWAS on REM sleep behavior disorder identified several genetic risk factors with potential effects on gene expression in different brain region (published in Nature Communications 2022, read the paper here).
     

  • We identified GALC as a gene potential gene involved in Parkinson's disease (published in Brain 2022, read the paper here).
     

  • The largest genetic study to date on dementia with Lewy bodies demonstrates overlap with both Parkinson's and Alzheimer diseases (published in Nature Genetics 2021, read the paper here).
     

  • Rare variants in BST1 and LAMP3 are associated with REM sleep behavior disorder (published in Neurology 2021, read the paper here).
     

  • Our new study suggests that the SYT11 and FGF20 genes are involved in Parkinson's disease (published in Brain 2021, read the paper here).
     

  • GBA mutations are important in REM sleep behavior disorder (published in Neurology 2020, read the paper here).
     

  • Genetic variance in the SNCA gene are associated with isolated REM sleep behavior disorder and may affect its conversion (published in Annals of Neurology 2020, read the paper here).
     

  • Using GWAS data, in collaboration with the NIH and the International Parkinson's Disease Genomics Consortium (IPDGC), we have identified genetic modifiers of GBA-associated Parkinson's disease (published in Brain 2020, read the paper here).
     

  • TMEM175 is an important gene in the different synucleinopathies, and is a potential modifier of GBA activity in humans (published in Annals of Neurology 2020, read the paper here).
     

  • We collaborated in the world's largest GWAS on Parkinson's disease, which identified numerous novel genomic loci associated with the disease (published in Lancet Neurology 2019, read the paper here).
     

  • We participated in the discovery of a novel gene causing hereditary spastic paraplegia, UBAP1 (published in The American Journal of Human Genetics 2019, read the paper here).
     

  • In collaboration with the NIH, we show that the underlying genetics of participants in clinical trials may have profound effects on the trial outcome, unrelated to the tested drug (published in Journal of Medical Genetics 2019, read the paper here).
     

  • We took part in the world's largest GWAS on restless legs syndrome, identifying 13 new genomic loci associated with risk for the disease (published in Lancet Neurology 2017, read the paper here).
     

  • Homozygous or compound heterozygous mutations in CAPN1 cause autosomal recessive hereditary spastic paraplegia (published in The American Journal of Human Genetics 2016, read the paper here).

bottom of page